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Live-virus vaccines activate both humoral and cell-mediated immunity, require only a single boosting, and generally
provide longer immune protection than killed or subunit vaccines. However, growth of live-virus vaccines must be
attenuated to minimize their potential pathogenic effects, and mechanisms of attenuation by conventional serial-
transfer viral adaptation are not well-understood. New methods of attenuation based on rational engineering of viral
genomes may offer a potentially greater control if one can link defined genetic modifications to changes in virus
growth. To begin to establish such links between genotype and growth phenotype, we developed a computer model
for the intracellular growth of vesicular stomatitis virus (VSV), a well-studied, nonsegmented, negative-stranded RNA
virus. Our model incorporated established regulatory mechanisms of VSV while integrating key wild-type infection
steps: hijacking of host resources, transcription, translation, and replication, followed by assembly and release of
progeny VSV particles. Generalization of the wild-type model to allow for genome rearrangements matched the
experimentally observed attenuation ranking for recombinant VSV strains that altered the genome position of their
nucleocapsid gene. Finally, our simulations captured previously reported experimental results showing how altering
the positions of other VSV genes has the potential to attenuate the VSV growth while overexpressing the immunogenic
VSV surface glycoprotein. Such models will facilitate the engineering of new live-virus vaccines by linking genomic
manipulations to controlled changes in virus gene-expression and growth.
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Introduction
Infections caused by viruses persistently threaten human
health. For example, 40 million, 350 million, and 170 million
people in the world are carrying human immunodeﬁciency
virus type 1 (HIV-1), hepatitis B virus (HBV), and hepatitis C
virus (HCV), respectively [1–3]. Annually 5% to 15% of the
global population is infected with inﬂuenza, resulting in
250,000 to 500,000 deaths [4]. Protection against viral
infections may be provided by inoculations with live-virus,
killed-virus, or subunit vaccines. Live-virus vaccines offer
advantages because they activate both humoral and cell-
mediated immunity, require only a single boosting, and
generally provide longer immune protection than other
forms of vaccines. However, they must be adequately
attenuated in their growth to minimize the possibility of
vaccine-induced pathogenic effects while retaining their
immunogenicity. Attenuation of live viruses has traditionally
been achieved by serially passaging viruses in tissue or cell
culture and adapting them to grow well on new cell types or
at elevated or reduced temperatures [5], a process that tends
to reduce their replicative ability and virulence in humans or
animals [6]. Such attenuation has historically been a highly
empirical process, where its mechanisms are often neither
known nor elucidated.
During the last decade the emergence of reverse genetics
techniques has created unprecedented opportunities to
better control viral attenuation [7–9]. Reverse genetics
enables the production of RNA viruses from cloned cDNA,
so speciﬁc mutations can be relatively easily introduced into
viruses. The challenge to engineering viruses for attenuation
then shifts from creating the variants to predicting how
speciﬁc genetic changes deﬁne or correlate with measurable
effects on virus growth. Such a challenge can be addressed
through the development of quantitative and mechanistic
models that map genome-level changes to the dynamics of
virus growth under different environmental conditions.
Models of intracellular virus growth aim to predict how
rapidly a virus-infected cell will produce virus progeny.
Inputs to such models include rates of constituent processes
such as entry of the virus into the cell, transcription of viral
mRNAs, translation of viral proteins, replication of viral
genomes, assembly of intermediates, and ﬁnally, production
and release of viral progeny. Decades of detailed biochemical,
biophysical, and genetic studies have, for diverse viruses,
contributed toward a level of mechanistic understanding of
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of virus growth have been developed for phage Qb [10], phage
T7 [11,12], HIV-1 [13], and inﬂuenza A virus [14].
How can a detailed model for the intracellular growth of a
virus be used to explore the behavior of mutant viruses that
encode alternative designs? As a starting point, one can
create alternative designs that reorder or rearrange the wild-
type genes or regulatory elements. Such genomic changes can
alter the timing and level of expression of different viral
genes, and thereby impact growth because the production of
viral progeny depends on the dynamic expression of viral
genes. Preliminary models of such alternative genome designs
can use the ‘‘language’’ of the wild-type virus. They retain the
parameters that characterize wild-type molecular interac-
tions, wild-type average rates of viral polymerase elongation,
and wild-type composition of progeny viruses, but they apply
them in a manner that reﬂects the reordering of wild-type
components in the engineered genome. For example, the
timing of expression for the genes of phage T7 during
infection maps closely to their sequential order on the T7
genome [15,16]. By relocating an essential early gene,
encoding the T7 RNA polymerase to downstream positions,
one delays initiation of transcription by the highly efﬁcient
T7 RNA polymerase and thereby attenuates phage growth
[17]. Preliminary models for the growth of phage carrying the
altered genomes, based on wild-type parameters, capture the
overall observed trends in attenuation. Here we expand this
approach to a mammalian virus of biomedical and agricul-
tural relevance: vesicular stomatitis virus (VSV).
VSV is a prototype negative-sense single-stranded RNA
(Mononegavirales, (-)ssRNA) virus and a member of the family
Rhabdoviridae [18,19], which includes rabies virus. Each VSV
particle has a single copy of an 11-kb genome carrying ﬁve
genes that encode nucleocapsid (N), phospho (P), matrix (M),
envelope (G), and polymerase (L) proteins. VSV is econom-
ically important because it can cause symptoms like those of
foot-and-mouth disease in livestock [19]. It offers several
advantages as a vaccine vector including low seropositivity in
humans, a capacity to accommodate foreign genes up to 40%
of its own genome size, and an established reverse genetics
[18,20]. Recombinant forms of VSV carrying foreign virus
genes that encode immunogenic proteins have been pro-
posed as potential vaccines against HIV, inﬂuenza, and
respiratory syncytial virus [21–25]. Less pathogenic but more
immunogenic VSV-based vaccines against infection by VSV
or other viruses are being sought.
Here we develop an in silico model of a VSV infection
cycle, incorporating known regulatory interactions and
mechanisms and relevant quantitative data from the liter-
ature of the past 40 years. These interactions and the
corresponding equation formulations are described in detail
in the model development section of Materials and Methods.
Using the model, we ﬁrst quantitatively analyze how the
intracellular growth of wild-type VSV directs host biosyn-
thetic resources toward VSV gene expression, synthesis of
progeny genomes, and pathway switching from the synthesis
of VSV intermediates to the production of VSV progeny. We
then reveal that the model captures experimental results
showing progressive attenuation of virus growth associated
with moving the N gene downstream from its wild-type
position. Finally, we use the model to predict how altering the
positions of other VSV genes and promoters may attenuate
the growth of VSV while increasing its potential capacity to
activate an adaptive immune response.
Results/Discussion
Quantitative Features of VSV Regulatory Mechanisms
Using our model with the established parameter set (Tables
1 and 2), we ﬁrst analyzed quantitatively and systematically
how the intracellular growth of VSV is regulated. The
improved understanding of the virus infection by this
model-based analysis may guide us to identify the key
regulatory components to manipulate for developing virus
mutants as possible vaccine or vector candidates.
Attenuation mechanism leads to unequally distributed
synthesis of viral mRNAs and proteins. The partial tran-
scription termination mechanism (or attenuation) is common
in (-)ssRNA viruses. This mechanism is important to satisfy
the different needs of each viral protein during its infection
cycle. Five attenuation factors for each intergenic region of
the VSV genome (Table 1 and Equation 8) were obtained
from the literature [18,19,26,27] and incorporated into our
model.
Owing to the step-wise release of polymerases from each
gene junction, our simulations estimated the gradual
decrease of VSV mRNA synthesis in the order of N . P .
M . G . L (Figure 1A). Compared with the most abundant N
mRNA, L mRNA is very scanty in infected baby hamster
kidney (BHK) cells (40 ; 140-fold less). The relative
production level of each protein matched the relative
availability of the corresponding mRNAs (Figure 1B) even
though different proteins degrade at different rates (Table 1).
Because of the different level of incorporation of each
protein into a single virion particle, as deﬁned by the protein
stoichiometry (Table 2, [28,29]), the relative levels of free viral
proteins in the cytoplasm develop differently from their
mRNA levels (Figure 1C). P protein is most abundant owing
to its low content in the virion, and L and N proteins are least
abundant. The persistently low level of N protein is related to
its immediate complexation with nascent genomes and anti-
genomes to make nucleocapsid particles during the repli-
cation step. Owing to the cyclic switching between tran-
scription and replication by the encapsidation process, the N
protein level is predicted to oscillate as shown in Figure 1C.
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Synopsis
The engineering of viral genomes provides ways not only to explore
viral regulatory mechanisms at a genomic level, but also to produce
recombinant viruses that may serve as vaccines, gene delivery
vectors, and oncolytic (tumor-killing) agents. However, the complex-
ity of interactions among viral and cellular components involved in
the life cycle of a virus can make it challenging to anticipate how
altering viral components will influence the overall behavior of the
virus. Lim, Lang, Lam, and Yin have developed a computer model
that begins to mechanistically account for key virus–cell interactions
in its predictions of viral intracellular development. Lim et al.’s model
was able to capture experimentally observed effects of gene
rearrangements on the levels and timing of viral protein expression
and virus progeny production, aspects that are important for the
design of live-virus vaccines. Refinement and extension of their
approach to current and other virus systems has the potential to
advance the application of viruses as therapeutic agents.
Mapping from Virus Genotype to Growth DynamicsAfter 9 h post-infection, our simulation predicts a signiﬁcant
decrease of free M proteins. This arises from the dominance
of the virion assembly process, which depletes M proteins,
compared with transcription and replication. In infected
murine delayed brain tumor (DBT) cells, similar distributions
of viral mRNAs and proteins were obtained (unpublished
data).
Higher demands for genomes are satisﬁed by the stronger
promoter of the anti-genome template relative to that of the
genome template. Anti-genome templates are only utilized to
amplify genomes, while genome templates are used to amplify
both anti-genomes and mRNAs, and they are also incorpo-
rated into virion progeny particles. The higher demands for
genome by these multiple tasks are satisﬁed by the stronger
promoter of the anti-genome template compared with that of
the genome template [30–32]. More polymerases bind to the
stronger promoter of the anti-genome, ultimately enhancing
the production of genomes over anti-genomes (Figure 2). In
our model the parameter Sprom measures the strength of the
anti-genomic promoter relative to that of the genomic
promoter (Table 1). The production ratio of genomes to
anti-genomes was estimated to be dynamically changed [33],
varying from one to 30 (wild-type VSV case (Sprom ¼ 5.4),
Figure S1). Such oscillatory changes in the production ratio
shown in Figure S1 follow from the on–off use of the genomes
for transcription or replication. They also arise owing to the
staggered shifting of dominant templates between genomes
and anti-genomes during replication. A large value of Sprom
favors use of anti-genome templates to replicate genomes.
However, as genome templates accumulate in large excess
relative to anti-genome templates, they successfully compete
for replication resources. Synthesis of anti-genomes then
dominates until they accumulate and serve again as the
dominant templates.
The virion production rate in BHK cells is at maximum 5–
10 h post-infection. In infected DBT cells, similar simulation
results were obtained except that the synthesis of genome-
sized viral RNAs continued for longer time (active until 15 h
post-infection, Figure 2).
Optimal utilization of genomic nucleocapsids. Genomic
nucleocapsids can either be used as templates for RNA
synthesis or they may be incorporated into progeny virions.
Their fate depends on levels of polymerase and M protein,
which respectively favor RNA synthesis or virion production
pathways, as well as on the extent to which association of the
nucleocapsid with M protein will dominate over association
with polymerase, described with the parameter Scond in our
model (Table 1). Because both RNA synthesis and virion
production are essential processes of the infection, extreme
values of Scond that favor one process over the other will be
Table 1. Model Parameters
Parameters Value
Viral parameters Elongation rate of polymerase [26] ke,pol ¼ 3.7 nt/s
Spacing between neighboring polymerases [49] Spol ¼ 170 nt
Strength of anti-genomic promoter relative to that of genomic promoter
a Sprom ¼ 5.43
Rate constant ratio of the associations of M protein and
polymerase with the genomic nucleocapsid
a
Scond ¼ 6.2 3 10
 5
Fraction of M protein bound to the plasma membrane [51] condM ¼ 0.1
Attenuation factors [18,19,26,27] /N / /P / /M / /G / /L ¼ 0.0 / 0.25 / 0.25 / 0.25 / 0.95
Degradation rate constants
N protein [58] kdp,N ¼ 3.5 3 10
 5 sec
 1
P protein [59] kdp,P ¼ 1.4 3 10
 6 sec
 1
M protein [58] kdp,M¼ 1.5 3 10
 4 sec
 1
G protein
b kdp,G ¼ 5.7 3 10
 5 sec
 1
L protein [59] (if concentration P protein   10 3 concentration L protein) kdp,L ¼ 1.2 3 10
 5 sec
 1
(if concentration P protein , 10 3 concentration L protein) kdp,L ¼ 4.3 3 10
 5 sec
 1
mRNA [60] kd,mRNA ¼ 1.9 3 10
 4 s
 1
nucleocapsid
c kd,nc ¼ 1.9 3 10
 5 s
 1
Host-dependent parameters Number of ribosomes in host cell [61] nrib ¼ 5 3 10
6
Elongation rate of ribosome [62] ke,rib ¼ 6 aa/s
Spacing between neighboring ribosomes
a (BHK/DBT) Srib ¼ 238.5/ 1425.5 nt
Degradation rate constant of host factors
a (BHK/DBT) kd,host ¼ 0.46 / 0.33 h
 1
Apparent binding rate constant
a (BHK / DBT) [63] kb ¼ 0.72 / 0.50 h
 1
aFive adjustable parameters. Other parameters were obtained from the literature.
bThe decay rate constant for G protein was taken as the average of the decay rate constants for the other four viral proteins.
cOwing to their increased stability by encapsidation, nucleocapsids are less degradable than naked mRNAs. It was assumed that the nucleocapsids of VSV are degraded 10-fold slower than
its mRNAs, and our simulation results were insensitive to this parameter.
DOI: 10.1371/journal.pcbi/0020116.t001
Table 2. Protein Composition of VSV Particle and Lengths of Its
Encoded Products
Proteins Length of
mRNA
a (nt)
Length of
Protein (aa)
Copies/Virion
N 1,326 422 1,258
P 814 265 466
M 831 229 1,826
G
b 1,665 511 1,205
L 6,373 2,109 50
aAll A residues of poly(A) tail were excluded.
bNonglycosylated precursor.
DOI: 10.1371/journal.pcbi/0020116.t002
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Mapping from Virus Genotype to Growth Dynamicsdetrimental for growth. For excessively large Scond, newly
synthesized genomic nucleocapsids would tend to be pre-
maturely incorporated into virion particles before they could
serve as templates for transcription and replication. On the
other hand, for extremely small Scond, genomic nucleocapsids
would be utilized primarily to produce viral RNA without
being packaged into viral progeny. Hence, an intermediate
parameter value is expected to be optimal for viral growth.
We estimated a possible range for the wild-type value of Scond
by ﬁtting our simulation results to previous experimental
observations by others (2.5 3 10
 5 to 1.0 3 10
 4, Figure S4).
Our simulations further indicate that this range of Scond is
near-optimal and optimal for VSV growth on BHK and DBT
cells, respectively (unpublished data).
Diversion and inhibition of host translation machinery
create a time window of opportunity for translation of viral
proteins. During the infection cycle, virus actively and
passively competes with the host for limited translation
resources by inhibiting host transcription and by amplifying
viral mRNAs, respectively. Viral leader–mRNA and M protein
play key roles in this inhibition [19,28,34–36]. As viral
components accumulate in the cytoplasm from the initiation
of infection, an ever-increasing fraction of host ribosomes are
available for viral mRNAs (Figure 3A, the fraction of
ribosomes associated with viral mRNAs is deﬁned by 1-
rib_host in Equation 26). However, the inhibition of host
macromolecular synthesis causes a failure to supply accessory
factors needed for initiation and elongation steps of trans-
lation, resulting in a reduction in the fraction of active
ribosomes over time (Figure 3A, as described by fdec in
Equation 25). These two mechanisms create a time window
when active ribosomes are maximally available for viral
translation in infected cells (Figure 3A, refer to the term (1-
rib_host)*fdec in Equation 27). The abundance of viral mRNAs
and the limitation imposed by ribosomal spacing determine
the fraction of the active ribosomes involved in translating
viral mRNAs (occupied ribosomes in Figure 3B, refer to
Equations 11 and 27). In our model, if the occupied active
ribosomes are less than the available ones (in this case the
number of free active ribosomes . 0), viral translation is fully
supported without any limitation of host machinery. In the
early infection stages up to 7 h and 13 h post-infection for
BHK and DBT cells, respectively, the host machinery is in
excess (Figure 3B). However, at later times viral translation
becomes limited by the host resources (in this case the number
of free active ribosomes ¼ 0). This limitation may cause a
transition from replication-dominant to assembly-dominant
infection stages because the replication requires the contin-
uous protein synthesis. As shown in Figure 3B, a small fraction
of ribosomes as active forms (less than 5% out of 5 3 10
6
ribosomes, Table 1) are utilized for viral translation.
Figure 1. Estimated Production of Viral mRNAs and Proteins from
Infected BHK Cells
All the viral proteins that are in the cytoplasm, plasma membrane, or
assembled virion particles are counted.
(A) Viral mRNAs.
(B) Viral proteins.
(C) Estimated levels of free viral proteins in infected BHK cells. Free viral
proteins include all the proteins in the cytoplasm or plasma membrane,
but exclude the proteins that are incorporated into nucleocapsids and
virion particles. Vex(0) ¼ 3.
DOI: 10.1371/journal.pcbi/0020116.g001
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Mapping from Virus Genotype to Growth DynamicsExperiments and simulations of VSV gene-order mutants.
For vaccine applications, one seeks to minimize viral
pathogenicity and maximize its immunogenicity. Based on
observed correlations between in vitro and in vivo results, we
assume here that the pathogenicity and the immunogenicity
of a virus are directly linked to the levels of progeny
production [20,37,38] and G protein expression in infected
cells [39,40], respectively. In the previous section we have
showed that various VSV regulatory mechanisms are involved
in maintaining balances, during infection, among viral
synthesis processes, which indirectly indicates the importance
of such balances for viral growth. Perturbations of such
balances by genetic or genomic manipulations could provide
ways to obtain viral phenotypes favorable to vaccine
applications. We ﬁrst test the predictive ability of our model
by comparing simulated protein expression and growth of
several gene-rearranged VSV strains with experimental
results. Later we employ the model to predict how various
genomic manipulations could attenuate virus growth and
increase G protein expression.
Protein expression rates of gene-rearranged viruses. The
stepwise decline in the transcription of genes more distant
from the 39-end region promoter highlights how gene order
affects gene expression in VSV. Advances in reverse genetics
have made it possible to create gene-rearranged virus strains
where the transcriptional attenuation mechanism then
creates altered levels of gene expression [7,9,18,20]. In one
study [18] the three internal genes, P, M, and G, were
permuted, and the resulting six possible VSV strains were
characterized. Relative rates of viral protein expression in
BHK cells were experimentally measured based on their
incorporation of [
35S]-labeled methionine for a one-hour
window at 4 h post-infection [18]. We extended our model to
simulate this experiment for mutants representing each gene-
order permutation and compared the model prediction with
the published results [18], as shown in Figure 4. All rates are
expressed relative to the synthesis rate of N protein, whose
corresponding gene was in position 1, closest to the 39 end of
the genome in all strain cases. Expression of gene L, in
position 5, was minimal in both simulations and experiments,
and the expression of all other genes was above 40%, a
feature of the experimental data that the simulation also
Figure 3. Hijacking of Host Translation Resources by Virus
(A) The estimated distributions between active (equipped with the
required accessory factors) and inactive (not equipped) ribosomes, and
between ribosomes available for viral and host mRNAs are shown.
‘‘- Time window -’’ indicates the time period during which viral
translation is actively supported by host ribosomes.
(B) The estimated numbers of ribosomes available for viral translation
and actually occupied by viral mRNAs are shown for the cases of infected
BHK and DBT cells. Non-occupied ribosomes are considered as free
ribosomes. When two lines coincide, no free ribosomes exist (all the
available ribosomes are occupied by viral mRNAs). Vex(0) ¼ 3.
DOI: 10.1371/journal.pcbi/0020116.g003
Figure 2. Estimated Distribution of Genome-Size Viral RNAs That Are
Produced in Infected BHK and DBT Cells
Virion and (-)NC indicate viral genomes that are incorporated into virion
particles and intracellular nucleocapsids, respectively. (þ)NC indicates
anti-genomes that are incorporated into intracellular nucleocapsids.
Vex(0) ¼ 3.
DOI: 10.1371/journal.pcbi/0020116.g002
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Mapping from Virus Genotype to Growth Dynamicscaptured. Most of the points fall close to the parity line,
indicating agreement between the simulation and experi-
ment. Noteworthy are two subsets of points. First, the four
circled points are exceptions to the general rule that gene
order determines the level of gene expression. These were
genes in the second position of the genomes that were
expressed essentially at the same rate as gene N, in the ﬁrst
position [18]. This result highlights that the expression rate of
protein is affected not only by its gene order, or correspond-
ing rate of mRNA production, but also by its length and
degradation rate. For a ﬁxed average rate of translational
elongation, longer gene products will tend to be produced
more slowly. Further, the net rate of protein production will
reﬂect the rates of both protein synthesis and protein
degradation. The model accounts for these contributions,
and for the circled genes such accounting appears to capture
unexpected high translation levels of genes in the second
position, which were measured by Ball et al. [18]. The second
sets of points, shown in two boxes, indicate mismatches
(Figure 4) that, in the most challenging scenario, could reﬂect
unknown strain-speciﬁc mechanisms that are not present in
our general gene-permutation model. However, one should
also note that the experiment is based on labeling and
quantifying proteins about 4 h post-infection. This relatively
early time point allows one to minimize potentially con-
founding inﬂuences of virion particle assembly and produc-
tion on cytoplasmic levels of viral proteins, but it also
represents a point before the majority of viral proteins have
been made (Figure 1B).
Growth of gene-rearranged viruses. We also employed our
model to predict the growth of VSV strains having the N gene
at four different locations (N1 [wild-type], N2, N3, and N4)
and then compared the simulation results with the exper-
imental data. N1, N2, N3, and N4 VSV strains have the gene
orders, 39-N-P-M-G-L-59 (N1), 39-P-N-M-G-L-59 (N2), 39-P-M-
N-G-L-59 (N3), 39-P-M-G-N-L-59 (N4), respectively. As shown
in Figure 5, our simulations qualitatively matched the
experimentally observed relative growth of the four strains
in BHK cells. The wild-type virus having the N gene at the
Figure 5. The Growth of Gene-Rearranged VSV Strains in BHK Cells
(A) Experimental data.
(B) Simulation results. The growth of the N1 VSV strain is the fitting
result, but the growth of the other three strains is the model prediction
result. Vex(0) ¼ 3.
DOI: 10.1371/journal.pcbi/0020116.g005
Figure 4. Relative Expression Rates of Viral Proteins in BHK Cells Infected
by Individual VSV Strain
The expression rate of each protein was normalized by that of N protein.
Therefore, the relative expression rate of N protein is defined as one. X
and Y coordinates of datapoints indicate the results of experiments and
simulations, respectively. All the experimental datapoints were obtained
from the literature [18]. The four datapoints in the circle denote the
relative protein expression rates for the genes located at the second
genome position in the cases of MGP, MPG, GPM, and GMP strains
having gene orders 39-N-M-G-P-L-59,3 9-N-M-P-G-L-59,3 9-N-G-P-M-L-59,
and 39-N-G-M-P-L-59, respectively. PMG and PGM strains have the gene
orders 39-N-P-M-G-L-59 and 39-N-P-G-M-L-59,r e s p e c t i v e l y .T h et w o
rectangular boxes include four datapoints where there are the largest
discrepancies between simulation and experimental results. Vex(0) ¼ 5.
DOI: 10.1371/journal.pcbi/0020116.g004
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Mapping from Virus Genotype to Growth Dynamicsﬁrst position on the genome grows best, followed by N2, N3,
and N4. This result is consistent with the previously suggested
hypothesis that relocation of the N gene to 39-distal positions
on the genome would be an efﬁcient way to attenuate VSV
for vaccine use [20]. The reduction in growth that follows
from moving the N gene likely reﬂects, at least in part, an
imbalance between replication and transcription. Insufﬁcient
production of N protein would reduce the extent of
encapsidation of nascent anti-genome and thereby allow
transcription to dominate over genome replication [41].
While the simulation matches the growth ranking, it did not
quantitatively match the experimental data. The predicted
variation in virion production (N1 ! N4: 4.7-fold decrease) is
smaller than the experimentally observed variation (N1 !
N4: 16.7-fold decrease). A potential source of this quantitative
difference was our neglect of mass action effects of N
proteins on the encapsidation process in our model;
encapsidation was simulated as an instantaneous process
when free N proteins were available. As shown above, our
model could capture the major effects of gene rearrangement
on viral growth and protein expression.
Effects of relative promoter strength on viral growth. The
genome and anti-genome of VSV are synthesized in unequal
amounts, determined by the differing strengths of their
promoters [19,31,33,39]. The stronger promoter of the anti-
genome allows viral polymerases to produce more genomes to
meet their demands as components of virion particles and as
templates for transcription and replication. To explore how
VSV growth is inﬂuenced by differences in the relative
strength of the genomic and anti-genomic promoters, we
predictedtheyieldofvirusonBHKandDBTcellsoverabroad
range of Sprom, as shown in Figure 6A. Small Sprom virus cannot
grow well because most polymerases would be associated with
genomes and tend to synthesize primarily anti-genomes. For
example, for Sprom equal to 0.1, infected BHK and DBT cells
make 5-fold and 26-fold fewer progeny than wild-type VSV
infected cells, respectively. However, large Sprom virus also
cannot grow well because most polymerases would preferen-
tially bind to newly synthesized anti-genomes, producing few
of the anti-genomes that are needed as templates to amplify
genomes. Our simulations predicted that values of 30 and 50
for Sprom would be optimal for VSV growth in BHK and DBT
cells,respectively(Figure6A).Theestimatedwild-typevalueof
Sprom of 5.4 gives VSV yields higher than 80% of their
maximum yields for both cell types (Figure 6A).
We speculate that a rational way to attenuate the
pathogenicity of the live wild-type virus would be to swap
its two promoters, giving an Sprom of (5.4)
 1. For this promoter
swap we predict virion production would be decreased by 3.3-
fold and 14.5-fold for infected BHK and DBT cells,
respectively, relative to wild-type. However, the extent of
growth attenuation by the promoter swapping can be higher
than the model prediction because the swapping may also
perturb viral transcription and virion assembly and budding
processes modulated by the signals encoded in the 39and 59
termini of the genome [42,43] that are not yet sufﬁciently
deﬁned to be included in the simulation.
Rational vaccine attenuation by double genomic manipu-
lations. Several variant VSV strains, including N1 through N4,
have been made by Ball and Wertz [18,20]. With an aim to
generate a potentially broader diversity of growth pheno-
types, we created and tested in silico VSV mutants by
combining N gene relocations with a range of Sprom. This is
a computationally simple task, but experimentally nontrivial.
For example, the VSV N4 with Sprom ¼ 0.1 produced a
simulated 38-fold fewer virus progeny than wild-type in BHK
Figure 6. The Effects of Relative Promoter Strength and N Gene
Rearrangement on the Growth Phenotype of VSV
(A) The balance of the production between genome and anti-genome is
determinedbythepromoterstrengthoftheanti-genomerelativetothatof
the genome (Sprom). Thechanges ofvirionproduction in BHK andDBTcells
by the variation of the parameter are observed. The black circles indicate
the virion productions of wild-type (Sprom¼5.4) in BHK and DBT cells.
(B) The extension of phenotypic variations by double genomic
manipulations was predicted. As an important phenotype of virus for
vaccine use, the changes of virion production by the relocation of N
gene along with the variation in the promoter strength of the anti-
genome relative to that of the genome (Sprom) are shown. The black
circle indicates the virion production of wild-type in BHK cells. Vex(0)¼3.
DOI: 10.1371/journal.pcbi/0020116.g006
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Mapping from Virus Genotype to Growth Dynamicscells (Figure 6B). It is interesting to note that this 38-fold
degree of growth attenuation is greater than the product of
the constituent attenuations (4.7 3 5.4 ¼ 25) that one
calculates by assuming that the effects were uncoupled. Such
nonmultiplicative effects of double genomic manipulations
on growth would be challenging to predict in the absence of a
quantitative model.
Modulation of VSV immunogenicity by gene shufﬂing. To
elicit a systematic immune response, live viral vaccines must
present or display neutralizing epitopes, typically through the
expression of viral surface proteins. Higher levels of antigen
expression have been found to correlate with more rapid and
potent induction of anti-viral antibodies [39,40]. As Flanagan
et al. suggested, the gene encoding G may be moved to other
positions in the VSV genome to modulate the expression of
the VSV surface glycoprotein G [39]. We generated in silico
ﬁve gene-shufﬂed VSV strains, having gene orders for the
three internal genes, MPG, MGP, PGM, GMP, and GPM, and
simulated levels of G protein in BHK cells infected with those
strains. Our simulation results were consistent with the idea
that the location of G gene affects the production of G
protein. The GPM strain gave the highest concentration of G
protein in the cytoplasm (almost 2-fold higher than that of
wild-type, Figure 7). However, in many cases effects of such
gene rearrangements can be difﬁcult to anticipate because of
the complexity of the involved interactions among viral
components. For example, the PGM strain showed only a level
of G protein expression similar to those of PMG (wt) and
MPG strains even though it has the G gene at an earlier
position than the other two strains (Figure 7).
For vaccine use we might aim to maximize the immuno-
genicity of VSV or a VSV-based vector through the
expression increase of VSV G gene or inserted foreign gene
while minimizing their potential pathogenicity by growth
attenuation. Given such design goals, speciﬁcally for a VSV
vaccine, we might prefer strain GPM, which showed the
highest expression of G protein (Figure 7) and the lowest
production of virions [18]. Toward such favorable features,
Flanagan et al. previously constructed three VSV strains
having the following gene orders: 39-G-N-P-M-L-59 (G1N2),
39P-M-G-N-L-59 (G3N4), and 39-G-P-M-N-L-59 (G1N4) [39].
These genome constructions were based on their intuitive
idea that translocations of G gene and N gene to earlier and
later positions, respectively, compared with wild-type, could
not only increase the expression of G protein, but also
attenuate virus growth [39]. This idea was supported by their
experimental results [39].
Seeking a more detailed correlation between locations of
the two genes and the viral phenotypes relevant to vaccine
application, we simulated in silico the growth of all mutants
that retain the gene order P – M – L of the wild-type, but
allow G and N to move, criteria that deﬁne 20 possible gene-
order permutations. The viral growth and the level of G
protein in infected BHK cells mainly depend on the locations
of N gene and G gene, respectively (Figure 8A and 8B), which
is consistent with the experimental results of Flanagan et al.
[39]. Further, if gene G is ﬁxed, then moving gene N closer to
the 39 promoter is predicted to increase protein G expression
(Figure 8B). Consistent with this prediction, Flanagan et al.
also observed a higher G protein expression for the G1N2
strain than for the G1N4 strain [39]. Enhanced replicative
ability of VSV strain by locating its N gene at an earlier
position in its genome can contribute to increasing the level
of G protein. If either gene N or gene G is located at the ﬁfth
position, then both levels of virus growth and G protein
expression are very low (Figure 8), because with such genome
organizations the stoichiometric amounts of N and G
proteins required for replication and assembly (Table 2,
[28,29]) cannot be reached. Our simulations with the BHK cell
parameters (Table 1) overall captured the experimentally
established relative growth of the VSV strains in BHK-21
cells, but the growth of the G3N4 strain was signiﬁcantly
overestimated compared with the experimental results [39]
(Table 3). The relevant mechanism for such a large discrep-
ancy between the simulation and the experimental results
remains to be elucidated.
The changes of protein expression levels by gene shufﬂing
can be a rational means to modify the viral features for
vaccine use. Robust synthesis of antigen by a highly attenuated
strain appears to be an effective vaccine strategy as Flanagan
et al. previously suggested. In addition to controlled attenu-
ation of virus growth, a potent vaccine should ideally elicit a
strong humoral or cell-mediated immune response.
Perspectives
In the era of highly advanced genetic technologies, we have
witnessed a turning point for the development of live viral
vaccines. Conventional empirical vaccine development pro-
cesses are now being replaced by more rational reverse-
genetics–based ones. With this trend, much attention will be
focused on mechanism-based design of less pathogenic and
more immunogenic virus stains. Mathematical models for
intracellular virus growth can support this design process by
providing a tool to systematically analyze the viral infection
regulatory network, identify critical regulatory mechanisms
or components for redirecting viral phenotypes, and reverse
engineer desirable phenotypes.
Figure 7. Estimated Levels of G Protein in BHK Cells Infected with Six
Gene-Shuffled VSV Strains
The intracellular level of G protein is highly dependent upon the location
of G gene on the viral genome. In the late infection stage, a large fraction
of G proteins are incorporated into progeny particles, which significantly
decreases the intracellular protein level. Vex(0) ¼ 3.
DOI: 10.1371/journal.pcbi/0020116.g007
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Experiments: Cell and virus culture. BHK cells were obtained from
I. Novella (Medical College of Ohio, Toledo, Ohio, United States) and
grown as monolayers at 37 8C in a humidiﬁed atmosphere containing
5% CO2. BHK growth medium was Minimal Essential Medium with
Earle’s salts (MEM) (Cellgro, Fisher Scientiﬁc, http://www.ﬁschersci.
com) containing 10% fetal bovine serum (FBS, HyClone, http://
www.hyclone.com), and 2 mM Glutamax I (Glu, Gibco, http://www.
invitrogen.com). DBT cells were obtained from J. Fleming (University
of Wisconsin-Madison, Madison, Wisconsin, United States) and grown
under the same environment as the BHK cells. DBT growth medium
was Dulbecco’s Modiﬁed Eagle Medium (Cellgro, Fisher Scientiﬁc)
containing 10% newborn calf serum (NCS, Hyclone), 4 mM Glutamax
I (Glu, Gibco), and 15 lM HEPES (Sigma, http://www.sigmaaldrich.
com). Both BHK and DBT cells were subcultured approximately every
third day. For subculture, cell monolayers were rinsed with Hanks
Balanced Salt Solution (HBSS, Fisher Scientiﬁc), incubated in 0.025%
trypsin/26 mM EDTA (Fisher Scientiﬁc) for 5 min, dispersed through
mixing, and then replated in fresh growth medium at 1:30 (BHK) or
1:15 dilution (DBT). No antibiotics were used, and cells were
subcultured for no more than 4 mo to minimize the effects of cell
senescence. Viability of cell populations always approached 100%, as
determined by trypan blue exclusion at the time of experiments. Four
gene-rearranged strains (N1–N4) of VSV were obtained from G.
Wertz (University of Alabama School of Medicine, Birmingham,
Alabama). Their genomic structures are as follows: 39-N-P-M-G-L-59
(N1), 39-P-N-M-G-L-59 (N2), 39-P-M-N-G-L-59 (N3), 39-P-M-G-N-L-59
(N4). Each strain of virus was bulked once on BHK cells at multiplicity
of infection (MOI) of 0.01 or 0.1 plaque-forming units per cell.
Infected cells were incubated in infection medium (MEM/Glu/2%
FBS) for 20–24 h. At the end of the incubation period, the medium
was harvested and passed through a 0.2-lm ﬁlter. The ﬁltered virus
solution was aliquoted and stored at  90 8C until use.
One-step infection of cell monolayers. Cells were harvested,
resuspended in growth medium, and plated into six-well plates at a
concentration of 5 3 10
5 cells per 2 ml per well. Plated cells were
returned to the incubator and allowed to grow overnight. The next
day, two representative cell monolayers were harvested and counted
to give an approximate number of cells per well. Each monolayer was
then incubated with 200 ll of virus inoculum (MOI 3) for 1 h to allow
virus adsorption. The plates were rocked gently every 20 min to
evenly distribute virions on the monolayers during the adsorption
step. After the adsorption period, the monolayers were rinsed twice
with 1 ml of HBSS and then placed under 2 ml of infection medium
for incubation. Medium samples of 200 ll including virion particles
were taken from each well at 2, 3, 4, 6, 8, 10, and 20 h post-
inoculation. Samples were kept frozen at 90 8C until their analysis by
the plaque assay.
Plaque assay. BHK cells were plated into six-well plates and
cultured to 90% conﬂuence. Culture medium was removed from each
well and replaced with 200 ll of serially diluted viral samples. The
inoculated monolayers were returned to the incubator for 1 h to
allow virus adsorption. The plates were rocked gently every 20 min.
At the end of the adsorption period, the inoculum was removed from
each monolayer sample and then replaced with 2 ml of agar overlay.
The agar overlay consisted of 0.6% weight/volume (w/v) agar (Agar
Nobel, Difco, BD Diagnostic Systems, http://www.bd.com). 5-Bromo-
29-deoxyuridine (B5002, Sigma) was added, at 100 lg/ml, to the agar
overlay of N3- and N4-infected samples to enhance plaque formation.
Following agar addition, the plates were allowed to cool at room
temperature for 30 min, returned to the incubator and incubated for
Table 3. Burst Size of VSV Strains
Strain Experiment (Flanagan et al.) Simulation
N1G4 (wt) 4,857 5,465
G1N2 1,714 2,498
G1N4 1,071 944
G3N4 7 1,172
Here, the burst size is defined by the number of produced infectious virion particles per
cell at 24 h post-infection.
DOI: 10.1371/journal.pcbi/0020116.t003
Figure 8. Predicted Levels of Virion Production and G Protein Expression
in BHK Cells Infected with VSV Strains (Total 20 Strains)
(A) Virion production.
(B) G protein expression.
The size of each circle shows the relative level for each VSV strain, and
the coordinate of each circle indicates the gene order in each strain’s
genome. The gray and white circles denote the cases of wild-type (N1G4)
and non–wild-type strains, respectively. Under the line there is no VSV
strain case (e.g., N1G1, N2G2, etc.). Vex(0) ¼ 3.
DOI: 10.1371/journal.pcbi/0020116.g008
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room temperature. The ﬁxative consisted of 4% (w/v) paraformalde-
hyde (VWR) and 5% (w/v) sucrose (Sigma) in 10 mM phosphate
buffered saline (PBS, Sigma) of pH 7.4. The agar overlay was then
removed, and each sample was rinsed twice with 2 ml of PBS. Gentian
violet diluted in methanol (0.01% (w/v), Sigma) was used, at 1 ml each,
to stain the samples.
Model development. Using algebraic and differential forms of
equations, our mathematical model aims to account for established
molecular processing steps in the development of VSV. Most model
parameters were extracted from the literature. However, ﬁve
parameters were obtained by ﬁtting our simulation results to
experimental data that were from the literature and our own
experiments. Key model parameters are given in Table 1, and
detailed descriptions of the model and parameter estimation process
are provided below, and in Protocol S1 and Figures S2 and S3,
respectively.
Virus binding and penetration. As shown in Figure 9A, VSV
initiates an infection by binding to a receptor such as phosphatidyl
serine, a lipid component in the plasma membrane [19,44]. After the
binding step, the VSV particle is endocytosed via a clathrin-coated
pit, and then penetrates intracellular vesicles such as endosomes by
membrane fusion [19,45–47]. The penetration leads to the release of
the encapsidated negative-sense viral genome and virus proteins into
the cytoplasm of the host cell. By assuming the binding step is rate-
determining [48], we lump these early steps from the binding to the
penetration into a ﬁrst-order expression:
dVb
dt
¼ kbVex ð1Þ
where Vb and Vex are the concentrations of bound and extracellular
virus particles, respectively, t is time, and kb is the apparent rate
constant for virus binding. After binding, we assume the bound virus
is immediately endocytosed and fused, and its genome and protein
components are instantaneously released into the cytoplasm at the
expense of the fused virus particle. The protein stoichiometry of a
single VSV particle and the lengths of each viral gene and protein are
summarized in Table 2, [28,29].
Population distribution of polymerases and nucleocapsids. Follow-
ing the release of the encapsidated genome and proteins into the
cytoplasm, VSV transcription is initiated. The viral transcription was
assumed to be independent of host–cell functions such as replication
[33]. Instead, the viral complex of L and P proteins, with a
stoichiometry of 1–3.6, was taken to function as polymerase in
transcription and replication [49]. In the absence of P protein, L
protein cannot bind to the genome or anti-genome [50]. After
binding to the 39 promoter regions of the genomic and anti-genomic
templates, the viral polymerase starts to synthesize its own RNA
transcription and replication products by elongating along the
templates. During transcription a fraction of elongating polymerases
terminate transcription by dissociating from the templates as they
encounter regulatory signals at intergenic regions [19,26]. In addition
to the regulated polymerase dissociation, time-dependent concen-
tration changes of the polymerases and the viral templates in the
cytoplasm inﬂuence the distribution of polymerases on the viral
templates during transcription and replication. Hence, the distribu-
tion of polymerases continuously varies over the viral templates,
ultimately determining the relative synthesis levels of mRNAs and
genome-size RNAs.
We simulate the transcription and replication processes by
considering the spatial–temporal distribution of template-associated
polymerases. We ﬁrst partition the viral genome and anti-genome
templates into 40 segments, excluding their 39 and 59 end regions,
which are the leader (Le) and trailer regions (Tr) for the genome, and
the complementary trailer (Trc) and complementary leader regions
(Lec) for the anti-genome, respectively (Figure 9B). For the genome
template that is used for transcription as well as for replication, we
specially grouped the segments into ﬁve genes (Figure 9B). We chose
40 as a minimum number for total segments which allows each gene
to be split into a speciﬁc integer number of segments, proportional to
the length of the gene. By considering the mechanisms for the
interactions between polymerase and the intergenic regulatory
sequences of the templates, as described below in the Transcription
section, we simulated the polymerase ﬂux into each segment over the
time elapsed from the initiation of transcription on each template.
Then we correlated the level of polymerase occupying each gene-
encoding section of the template with the synthesis rate of each
corresponding viral mRNA. In a similar way, the distribution of
polymerases on the replication templates was correlated with the
synthesis rate of viral genome-sized RNA. Such explicit treatment of
polymerase spatial distributions on the viral genome and anti-
genome templates was central to modeling the growth of wild-type
and gene-rearranged virus strains. This treatment systematically
accounts for polymerization-associated time delays and the polymer-
ase ﬂuxes into each template segment.
Before estimating the polymerase ﬂux, we need to ﬁgure out how
the polymerase complex and M protein compete with each other for
binding to the genomic nucleocapsids as well as how the polymerases
bound to nucleocapsids are subsequently distributed to one of three
possible tasks: transcription, replication of genome, or replication of
anti-genome. In our model we assume that the genomic templates
(negative-sense nucleocapsids) whose promoters (leader regions) are
free of polymerases are available for association with free polymerase
or M protein. We further assume that the associations of the free
genomic templates by M proteins or polymerases take place
instantaneously:
ð Þnc   poll
Spol
ll
¼ ð ÞncM;new þ ð Þncpol;new ð2Þ
where (-)nc,( -)nc
M,new, and (-)nc
pol,new are the concentrations of total
genomic nucleocapsids and subsets of genomic nucleocapsids whose
promoters are newly occupied by M protein and polymerase,
respectively. Spol is the spacing between neighboring polymerases on
the genomic or anti-genomic template, poll is the concentration of
polymerases bound to the promoter region (Le) of the genomic
template, and ll is the length of the promoter region. Speciﬁcally, the
second term in the left-hand side of the equation denotes the
concentration of the genomic templates whose promoters are
currently occupied by polymerases. In our model the concentration
of the genomic nucleocapsids whose promoters are bound to
polymerases and the concentration of the polymerases bound to the
promoters of the genomic nucleocapsids are interchangeable with
each other by the factors (ll/Spol) and (Spol/ll), respectively. The binding
of M protein or polymerase initiates reactions leading to virion
assembly or RNAsynthesis, respectively. Becausethe initiationofRNA
synthesis by the polymerase requires a ﬁnite time, a space between
adjacent polymerases on the template (Spol) would be maintained
during infection, assuming a ﬁxed elongation rate. With these
considerations, one may expect that at any time the concentration
of nucleocapsids available for the new binding of the free proteins is
inversely proportional to the concentration of polymerases currently
bound to the leader region of the genomic nucleocapsids (poll) and the
polymerase spacing (Spol) as shown in the second term of Equation 2.
The ratio of (-)nc
M,new to (-)nc
pol,new is determined by the ratio of the
association rates of M protein and polymerase with the genomic
nucleocapsid, which is further a function of the rate constants and
relative amounts of the corresponding free components in the
cytosol:
ð ÞncM;new
ð Þncpol;new ¼
rasso;M
rasso;pol
¼
kMð1   condMÞM
kpolðL   trans   poltotalÞ
¼
Scondð1   condMÞM
L   trans   poltotal
ð3Þ
where rasso,M and rasso,pol are the rates of the associations of M protein
and polymerase with the genomic nucleocapsid, respectively, and kM
and kpol are the rate constants for each association reaction,
respectively. Scond denotes the ratio of the two rate constants (¼kM/
kpol). Unlike L protein, 10% of synthesized M proteins are associated
with the plasma membrane [51]. In Equation 3, condM is the fraction of
M proteins associated with the plasma membrane, trans is the fraction
of L proteins satisfying the polymerase stoichiometry with P protein,
poltotal is the total concentration of polymerases associated at the time
with nucleocapsids, and M and L are the total concentrations of M
and L proteins not assembled into viral progeny. If the concentration
of P protein (P) is larger than 3.6-fold concentration of L protein,
then trans is equal to 1. Otherwise, trans is equal to P/(3.6L). In our
model, M and L proteins compete for free genomic nucleocapsids,
and the condensed nucleocapsids, owing to their association with M
proteins, cannot be utilized for transcription or replication [19].
From Equations 2 and 3, the newly occupied nucleocapsids by
polymerases ((-)nc
pol,new) can be calculated:
ð Þncpol;new ¼ ðð Þnc   poll
Spol
ll
Þ
1
Scondð1 condMÞM
L trans poltotalþ1
ð4Þ
In the same way, given Spol, the concentration of positive-sense anti-
genomic nucleocapsids available for binding to polymerases would be
((þ)nc – poltrc(Spol/ltrc)), where (þ)nc is the total concentration of anti-
genomic nucleocapsids, poltrc is the concentration of the polymerases
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length of the promoter region. Because the anti-genome has a
stronger promoter than the genome [19,31], which is quantiﬁed by
Sprom in our model, Sprom-fold, more polymerases bind to the promoter
of the anti-genome than to that of the genome. Under the limitation
of free polymerase complex, the concentration of the polymerases
newly binding to the promoters of the genomes or the anti-genomes
(polterm
new) could be described as follows:
Figure 9. Schematic Descriptions
(A) Infection cycle of VSV.
(B) Segmentation of genome-size viral templates to simulate the spatial–temporal changes of polymerase concentration on the templates.
(C) VSV partial transcription termination (or attenuation) mechanism.
DOI: 10.1371/journal.pcbi/0020116.g009
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term ¼ min
 
  ðÞ ncpol;new ll
Spol
þ
 
ðþÞnc
ltrc
Spol
Sprom   poltrc
 
;
L   trans   poltotal
!
ð5Þ
where Sprom is the strength of the anti-genomic promoter relative to
that of the genomic promoter, and min(A,B) equals the smaller of A
and B. The distribution of newly bound polymerases between
genomic and anti-genomic templates is determined by the concen-
trations of the available free templates of each type and the relative
strengths of their promoters:
polnew
l ¼
ð Þncpol;new ll
Spol
ð Þncpol;new ll
Spol þ ½ðþÞnc ltrc
Spol Sprom   poltrc 
poltermnew ð6aÞ
polnew
trc ¼ polnew
term   polnew
1 ð6bÞ
where poltrc
new is the concentration of the polymerases newly binding
to the complementary trailer region (promoter) of the anti-genome.
The polymerases newly binding or already bound to the promoters of
the genomes and anti-genomes start viral RNA synthesis as tran-
scription or replication process.
Transcription. The viral polymerase on the leader region of the
genome starts either transcription or replication. If there are
sufﬁcient N proteins, transcription is inhibited by the encapsidation
of nascent positive-sense RNAs by N proteins; then replication
dominates transcription [41,52,53]. In contrast, if there are insufﬁ-
cient free N proteins, then transcription dominates replication. In
the model we correlate the extent of transcription dominance with
the availability of N proteins by introducing a factor, encap. This
factor is deﬁned as the ratio of the number of free N proteins to the
number required to encapsidate all available nascent genome-sized
viral RNAs. Only nocap (¼ 1   encap) of the polymerases bound to the
genomic promoters can start the transcription:
dpolN;1
dt
¼ ke;polðð1   /NÞnocap
poll
ll
 
nsec;N
lmRNA;N
polN;1Þð 7Þ
where polN,1 is the concentration of the polymerases located at the
ﬁrst segment of the N gene (Figure 9C), ke,pol is the elongation rate of
polymerase, /N is the attenuation factor for N gene, nsec,N is the total
number of the segments of N gene, and lmRNA,N is the length of N
mRNA (Table 2, [28,29]). The genome segments are continuously
charged with incoming polymerases and discharged with outgoing
polymerases with a rate of ke,pol (Equations 7–9). If the polymerase
input to the leader region of the genome is decreased owing to a lack
of free polymerases, then the polymerase concentrations downstream
of the leader region will be subsequently reduced (Figure 9C). There
are conserved intergenic sequences involved in letting a fraction of
viral polymerases release from the genome template at intergenic
sections during transcription, which is so-called partial transcription
termination or attenuation (Figure 9C) [18,19]. Because the tran-
scription is initiated from the 39 end promoter, the attenuation
mechanism causes genes more proximal to the 39 end to be more
highly expressed, which ultimately leads to an unequal concentration
distribution of viral mRNAs. The extents of partial transcription
termination are quantiﬁed by the attenuation factors, /i, in our
model (Figure 9C). These are 0/0.25/0.25/0.25/0.05 for leader–N/N–P/
P–M/M–G/G–L intergenic regions, respectively [18,19,26,27]. /i
fraction of polymerases are released at intergenic region i. With
Equations 7–9, we simulate the polymerase ﬂux into each gene
segment, which is proportional to the elongation rate of polymerase,
but inversely proportional to the extent of attenuation:
dpoli;j
dt
¼ ke;polðð1   /iÞ
nsec;i 1
lmRNA;i 1
poli 1;nsec;i 1
 
nsec;i
lmRNA;i
poli; jÞj ¼ 1; i ¼ P; M; G; L ð8Þ
dpoli;j
dt
¼ ke;pol
nsec;i
lmRNA;i
ðpoli;j 1   poli;jÞj 6¼ 1; i ¼ N; P; M; G; L ð9Þ
where poli,j is the concentration of the polymerases located at the jth
segment of gene i, and i 1 indicates the prior gene of gene i. The
amount of newly synthesized mRNAs for each gene is determined by
the concentration of polymerases occupying each gene section on the
genome template and the decay rates of the mRNAs:
dmRNAi
dt
¼
ke;pol
lmRNA;i
polt;i   kd;mRNA mRNAi ð10Þ
where mRNAi is concentration of mRNAs for gene i, kd,mRNA is the
decay rate constant of mRNA that is the same for all ﬁve viral mRNAs
[54], and polt,i is the total concentration of the polymerases occupying
on the ith gene.
Our formulation for transcription assumes that the synthesis of
viral mRNAs is rate-controlled by the transcription initiation as well
as the elongation of polymerase. Transcription initiation rate is
parameterized by the spacing between neighboring polymerases in
our model. At a given polymerase elongation rate, the larger
polymerase spacing indicates the lower rate of transcription
initiation. Transcription initiation modulates the input of poly-
merases to the leader region of the genome.
Translation. We consider that both translation initiation and
polypeptide chain elongation contribute to the rate of viral protein
synthesis. The translation initiation rate is parameterized by the
ribosomal spacing. In our model we ﬁrst calculated the number of
ribosomes involved in viral translation by considering the maximum
concentration of the ribosomes bound to viral mRNAs at a ﬁxed
ribosomal spacing:
rib ¼ min
 
nrib;avail;
X L
j¼N
lmRNA;j mRNAj
Srib
!
ð11Þ
where rib and nrib,avail are the concentrations of the ribosomes actually
involved in viral translation and the ribosomes available for viral
translation, respectively, and Srib is the spacing between neighboring
ribosomes.
The ribosomes involved in viral translation (rib) are allocated to the
ﬁve types of viral mRNAs according to their length and abundance,
assuming that each viral mRNA has the same efﬁciency of translation
initiation [55]:
ribi ¼
lmRNA;i mRNAi
X L
j¼N
lmRNA;j mRNAj
ðribÞð 12Þ
where ribi is the concentration of the ribosomes assigned to mRNA i.
The synthesis rate of each viral protein depends on the elongation
rate of the ribosome, linear density of ribosomes on its correspond-
ing mRNA, and its ﬁrst-order decay rate:
dpi
dt
¼
ke;rib
lp;i
ribi   kdp;i pi i ¼ P;M;G;L ð13Þ
where pi is the concentration of protein i, ke,rib is the elongation rate
of ribosome, lp,i is the length of protein i, and kdp,i is the decay rate
constant of protein i.
We also accounted for the consumption of free N proteins during
the encapsidation of genome-length nascent RNAs and assumed that
the degradation of nucleocapsids yielded intact N proteins:
dpi
dt
¼
ke;rib
lp;i
ribi   kdp;i pi   niðencap   ke;pol
poltr
ltr
þ
pollec
llec
  
 kd;ncððþÞnc þ ð ÞncÞÞ i ¼ N ð14Þ
where nN is the stoichiometry of N protein in a single nucleocapsid or
virion progeny (Table 2, [28,29]), poltr and pollec are the concentrations
of the polymerases located on the trailer and complementary leader
regions of the genomes and the anti-genomes, respectively, llec (¼ll)i s
the length of the complementary leader region, and kd,nc is the decay
rate constant of nucleocapsid. As progeny virions are assembled, the
concentration of each protein is reduced by the amount correspond-
ing to its stoichiometry in a single virion particle.
Replication. We assumed that N protein regulates the switch of the
role of polymerase between transcription and replication by
encapsidating the newly synthesized RNAs [41,52]. The polymerase
that starts the replication at the leader region of the genome requires
further supply of N proteins to skip the attenuation signals at each
gene junction and thereby to complete each round of replication.
Depending on the availability of N proteins, nocap(¼1-encap) fraction
of polymerases terminate the replication at each gene junction in our
model:
dpolr;n;N;1
dt
¼ ke;polðencap
poll
ll
 
nsec;N
lmRNA;N
polr;n;N;1Þð 15Þ
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Mapping from Virus Genotype to Growth Dynamicswhere polr,n,N,1 is the concentration of the replicating polymerases on
the ﬁrst segment of the N gene section in the negative-sense genomic
nucleocapsid.
dpolr;n;i;1
dt
¼ ke;polðencap
nsec;i 1
lmRNA;i 1
polr;n;i 1;nsec;i 1
 
nsec;i
lmRNA;i
polr;n;i;1Þ i ¼ P;M;G;L ð16Þ
where polr,n,i,1 and polr,n,i-1,nsec,i-1 are the concentrations of the
replicating polymerases on the ﬁrst segment of gene i, and on the
last segment of gene i 1, respectively.
The level of polymerases that scan through the whole genome (poltr)
determines the amount of newly synthesized anti-genomic nucleo-
capsids, (þ)nc:
dpoltr
dt
¼ ke;pol
nsec;i
lmRNA;i
polr;n;i;j  
poltr
ltr
  
i ¼ L; j ¼ nsec;L ð17Þ
dðþÞnc
dt
¼ ke;pol encap
poltr
ltr
  kd;ncðþÞnc ð18Þ
where ltr (¼ ltrc) is the length of the trailer region of the genome. We
also considered the ﬁrst-order kinetics for the decay of anti-genomic
nucleocapsid.
The synthesis and decay of genomic nucleocapsids are described in
the same way as for those of the anti-genomic nucleocapsids except
that the polymerases on the anti-genomic templates are not released
at intergenic regions:
dpolr;p;j
dt
¼ ke;polðencap
poltrc
ltrc
 
nsec
l   ltrc   llec
polr;p;jÞ j ¼ 1 ð19Þ
where polr,p,j is the concentration of the replicating polymerases on
the jth segment of the positive-sense anti-genomic nucleocapsids, l is
the total length of the genome, and nsec is the total number of
segments of the genome (Figure 9B).
dpolr;p;j
dt
¼ ke;pol
nsec
l   ltrc   llec
ðpolr;p;j   1   polr;p;jÞ j ¼ 2; ...nsec ð20Þ
dpollec
dt
¼ ke;pol
nsec
l   ltrc   llec
polr;p;nsec  
pollec
llec
  
ð21Þ
dð Þnc
dt
¼ ke;pole ncap  
pollec
llec
  kd;ncð Þnc ð22Þ
In our model, non-encapsidated nascent genome and anti-genome
fragments are released from polymerases and immediately degraded.
As polymerases leave the promoter regions by moving toward the
downstream sequences, the concentration of polymerases on the
promoters will decrease. The dynamic changes of the polymerase
concentrations on the promoters of the genomic and the anti-
genomic templates are ﬁnally described, respectively:
poll;nþ1 ¼ poll;n þ polnew
l;n   poll leave;n ð23Þ
where poll-leave is the concentration of the polymerases leaving the
genomic promoters, O,n and O,nþ1 are the concentrations of a
component (O) at time n and time nþ1 (in our numerical integration,
time nþ1   time n ¼ Dt), respectively.
poltrc;nþ1 ¼ poltrc;n þ polnew
trc;n   poltrc leave;n ð24Þ
where poltrc-leave is the concentration of the polymerases leaving the
anti-genomic promoters.
Assembly and budding. We assume that the condensation of
negative-sense nucleocapsid by M protein initiates the virion
assembly and the condensed nucleocapsids are not degraded in the
same manner as virion progeny. Whenever the requirement for the
stoichiometric amounts of proteins is satisﬁed, progeny virions are
instantaneously assembled and released to the extracellular space.
The time required for the condensation of the negative-sense
nucleocapsid, the assembly, and the budding of progeny virion was
assumed to be negligible relative to the preceding steps.
Host cell. In our model, the host cell provides unlimited building
blocks such as nucleoside triphosphates and amino acids for the
growth of virus. However, as viral components accumulate during the
course of infection, some key host components for translation such as
initiation and elongation factors may be depleted [28,63,56]. Two
main viral products, leader-mRNA and M protein, contribute to the
deﬁciency by inhibiting the synthesis of host macromolecules at the
transcription level [19,28,35,36]. Because leader-mRNA starts to
accumulate soon after the initiation of infection, and a small amount
of the component is enough to trigger the inhibition [28,35], the pool
of host factors is continuously reduced from the onset of infection.
We quantify this reduction with a single decay rate constant speciﬁc
to the type of host cell:
fdec ¼ expð kd;hosttÞð 25Þ
where fdec is the level of host translation factors at time t, relative to
that of the initial state of the cell before infection (at t¼0), and kd,host
is the decay rate constant.
The inhibition by the leader mRNA causes a ﬁrst-order decay of the
host factors, resulting in a shortage of the ribosomes equipped with
the accessory factors for viral translation in the late infection stage in
our model. Unlike viral transcription and replication, viral translation
is directly affected by the decay of host factors since it depends
entirely on host machinery. In the early infection, host mRNAs
outnumber viral mRNAs and thereby successfully compete for the
host translation machinery. However, the newly synthesized M
proteins inhibit the host transcription initiation and the export of
host mRNAs from the nucleus to the cytoplasm [57], thereby causing a
gradual shift in translation from host mRNAs to viral mRNAs. For our
model we assumed that the potency of the inhibition by the M protein
was independent of the type of cell and its differentiation state [36],
and we developed an empirical formula using available experimental
data from the literature [36] to account for the competition between
hostand viral mRNAs for ribosomes. Lyles at al. cotransfectedthe host
cells with VSV M mRNA and chloramphenicol acetyl transferase
(CAT) plasmid DNA, and then they quantiﬁed the expression of CAT
based on its activity, as a function of the expression of VSV M protein
[36]. In their experiment the gene expression of CAT was more
reduced at higher M protein expression levels. We assume that the
decrease of the expression of CAT (or its activity decrease) is
proportional to the decrease of the occupancy of host mRNAs by
the translation machinery. Using their experimental data, the
occupancy of host mRNAs by the translation machinery is correlated
with the number of newly synthesized M proteins in the cytoplasm:
rib host ¼ 1:88   103ðMcellð1   condMÞÞ
 0:9582 ð26Þ
where rib_host is the fraction of the translation machinery associated
with host mRNAs, and Mcell is the total number of newly synthesized
M proteins per cell.
Considering the decay of host factors and the competition between
host and viral mRNAs, we could derive a formula to quantify the
number of the fully functional ribosomes that are available for the
viral protein synthesis over time post-infection (nribavail):
nribavail ¼ nribð1   rib hostÞfdec ð27Þ
where nrib denotes the total concentration of ribosomes whether or
not they incorporate all the required accessory factors for their
translation function.
Although the ribosomes distribute into membrane-bound and
cytoplasmic forms, each class supporting the syntheses of the viral G
protein and the other four viral proteins (N, P, M, and L),
respectively, we treated the ribosomes in our model as one
population.
Initial condition for simulation. The initial condition for our
simulation is set by a ﬁxed number of infectious extracellular virus
particles per cell (Vex(0)). At time zero (t ¼ 0), the number of bound
virus particles and the level of all viral components within cells are
zero. In our model, binding of extracellular virus particles to cells
reduces their level (Equation 1), and an encapsidated genome and
stoichiometric amounts of viral proteins (Table 2, [28,29]) are then
immediately released from each bound virus particle to the
cytoplasm. Speciﬁcally, we assume that all N proteins from a bound
virus particle are released as a form of encapsidated genome
complex. Downstream processes, beginning with transcription, are
then initiated. In our simulation, viral infection starts with rib_host¼
0.99 (with rib_host ¼ 0.9, ; 0.9995 simulations showed the same
results). Other key model parameters for simulation are summarized
in Table 1. In addition, a nomenclature list is shown in Table 4.
Supporting Information
Figure S1. Ratio of Genome to Anti-Genome During Simulated VSV
Infection Depends on Relative Promoter Strengths
The relative strength of the anti-genomic promoter relative to the
genomic promoter is given by Sprom. PI stands for time post-infection.
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Parameter Description Unit
condM Fraction of M proteins associated with plasma membrane –
encap Fraction of polymerases starting replication out of polymerases bound to genomic promoters –
fdec Level of host translation factors relative to that of the initial state of cells before infection –
G Concentration of G proteins in number Number/cell
kb Apparent rate constant for virus binding sec
 1
kd,host Rate constant of degradation of host translation factors sec
 1
kd,mRNA Rate constant of mRNA decay sec
 1
kd,nc Rate constant of nucleocapsid decay sec
 1
kdp,i Rate constant of decay of protein i sec
 1
ke,pol Elongation rate of polymerase nt/sec
ke,rib Elongation rate of ribosome aa/sec
kM Rate constant of association of M protein with genomic nucleocapsid sec
 1
kpol Rate constant of association of polymerase with genomic nucleocapsid sec
 1
L Concentration of L proteins Number/cell
l Length of VSV genome nt
ll Length of genomic promoter (or leader (Le) region of VSV genome) nt
llec Length of the complementary leader region of VSV genome nt
lmRNA,i Length of mRNA i nt
lp,i Length of protein i aa
ltr Length of the trailer region of VSV genome nt
ltrc Length of anti-genomic promoter nt
M Concentration of M proteins Number/cell
Mcell Total concentration of newly synthesized M proteins Number/cell
mRNAi Concentration of mRNAs for gene i Number/cell
N: Concentration of N proteins Number/cell
(þ)nc Total concentration of anti-genomic nucleocapsids Number/cell
(-)nc Total concentration of genomic nucleocapsids Number/cell
(-)nc
M,new Concentration of genomic nucleocapsids newly occupied by M proteins Number/cell
(-)nc
pol,new Concentration of genomic nucleocapsids newly occupied by polymerases Number/cell
ni Stoichiometry of viral protein i in a single virion progeny –
nocap Fraction of polymerases starting transcription out of polymerases bound to genomic promoters –
nrib,avail Concentration of ribosomes available for viral translation Number/cell
nsec Total number of segments of VSV genome –
nsec,i Number of segments for gene i –
P Concentration of phosphoproteins Number/cell
pi Concentration of protein i Number/cell
poli,j Concentration of polymerases located at the jth segment of gene i Number/cell
poll Concentration of polymerases bound to genomic promoters Number/cell
poll
new Concentration of polymerases newly binding to genomic promoters Number/cell
poll-leave Concentration of polymerases leaving genomic promoters Number/cell
pollec Concentration of polymerases bound to the complementary trailer regions Number/cell
polr,n,i,j Concentration of replicating polymerases on the jth segment of gene i Number/cell
polr,p,j Concentration of replicating polymerases on the jth segment of anti-genomic nucleocapsids Number/cell
polt,i Total concentration of polymerases occupying on gene i Number/cell
polterm
new Concentration of polymerases newly binding to genomic or anti-genomic promoters Number/cell
poltotal Total concentration of polymerases associated with nucleocapsids Number/cell
poltr Concentration of polymerases bound to the trailer regions Number/cell
poltrc Concentration of polymerases bound to anti-genomic promoters Number/cell
poltrc
new Concentration of polymerases newly binding to anti-genomic promoters Number/cell
poltrc-leave Concentration of polymerases leaving anti-genomic promoters Number/cell
rib Concentration of ribosomes actually involved in viral translation Number/cell
ribi Concentration of ribosomes assigned to mRNAi Number/cell
rib_host Fraction of translation machinery associated with host mRNAs –
Scond kM/kpol –
Spol Spacing between neighboring polymerases on genomic or anti-genomic templates nt
Sprom Strength of anti-genomic promoter relative to that of genomic promoter –
Srib Spacing between neighboring ribosomes on viral mRNAs nt
t Time S
trans Fraction of L proteins satisfying the polymerase stoichiometry with P protein –
Vb Concentration of bound virus particles Number/cell
Vex Concentration of extracellular virus particles Number/cell
/i Attenuation factor for gene i –
DOI: 10.1371/journal.pcbi/0020116.5004
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was three.
Found at DOI: 10.1371/journal.pcbi/0020116.sg001 (286 KB TIF).
Figure S2. Model Fitting with Experimental Data
Two host parameters (Srib and kd,host) were obtained by ﬁtting our
model with the one-step growth of wild-type virus in BHK or DBT
cells (symbols). The simulation results for viral one-step growth are
denoted by lines. Initial number of infectious extracellular virus
particles per cell was three.
Found at DOI: 10.1371/journal.pcbi/0020116.sg002 (635 KB TIF).
Figure S3. Flowchart of Iterative Parameter Estimation Process
Found at DOI: 10.1371/journal.pcbi/0020116.sg003 (714 KB TIF).
Figure S4. Productivity Ranking of Six Gene-Shufﬂed Viruses
Provides Parameter Constraint
For each value of Scond and its corresponding host parameter values
(kd,host and Srib), the virus productivity of each gene-shufﬂed virus in
BHK cells was determined and normalized by the highest productiv-
ity. Simulated rankings of six strains matched experimentally
observed rankings [9] over a narrow range of Scond, indicated by the
bar. Initial number of infectious extracellular virus particles per cell
was three.
Found at DOI: 10.1371/journal.pcbi/0020116.sg004 (872 KB TIF).
Protocol S1. Parameter Estimation
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